BioSpace News Archive

Better Therapeutics, Inc. announced the details of its poster presentation at the European Association for the Study of the Liver Congress 2023, being held from June 21-24 in Vienna, Austria.

RELIEF THERAPEUTICS Holding SA announced it has entered into a definitive agreement for the sale and purchase in a private placement of 1,500,000 ordinary shares of Relief Therapeutics and warrants to purchase up to 1,500,000 ordinary shares at a purchase price of CHF 3.33 per share and associated warrant.

Merck, known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-811 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with trastuzumab and chemotherapy met one of its dual primary endpoints of progression-free survival for the first-line treatment of human epidermal growth factor receptor 2 -positive advanced gastric or gastroesophageal junction adenocarcinoma.

Abcam plc, a global leader in the supply of life science research tools, filed and mailed a shareholder circular calling an Extraordinary General Meeting to be held on July 12, 2023 at 2:00pm || 9:00am.

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) is pleased to announce that it has recruited two highly experienced lead principal investigators (PIs) for the IND opening Phase 2/3 clinical trial investigating IHL-42X for treatment of obstructive sleep apnoea (‘OSA’).

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”) today announced that its President and CEO, Robert E. Hoffman and its Chief Scientific Officer, Dennis Brown, Ph.D., will participate in a fireside chat at the Maxim Group Virtual Conference on Tuesday, June 20, 2023 at 4:30 pm ET.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023 at 11:30 a.m. ET.

Panbela Therapeutics, Inc. announced the pricing of a public offering of 2,270,000 shares of its common stock or pre-funded warrants in lieu thereof and two classes of warrants to purchase up to an aggregate of 4,540,000 shares of its common stock at a purchase price of $3.75 per share and associated Public Warrants.

RaySearch Laboratories AB announces that the Australian Bragg Centre for Proton Therapy and Research in Adelaide, Australia has placed an order for the oncology information system RayCare®*.

Microbot Medical Inc. is encouraged by the continued participation and level of enthusiasm being demonstrated by the Key Opinion Leaders globally who are using the LIBERTY® Robotic Surgical System during the Company’s pre-clinical animal studies.